

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Biocure Technology Inc. (the "Issuer").

Trading Symbol: CURE

Number of Outstanding Listed Securities: 96,937,001

Date: June 3, 2019

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Biocure Technology Inc.'s Biocure Pharm Corp. (BPK) has entered into an agreement with Pharos Vaccine Inc. for the development of overseas market of CAR-T-cell products on an exclusive basis. The two companies will work together in developing anti-CD19 CAR-T-cell therapy products, conducting preclinical and clinical trials, and commercializing anti-CD19 CAR-T-cell therapy products overseas to treat leukemia and lymphoma patients. Some of the highlights of collaborative research and development work scopes in the agreement include:

1. Manufacture products for preclinical trial of contract product;
2. Preclinical trial of contract product;
3. Manufacture three batches of test product for clinical trial application of contract product;
4. Application for clinical trial of contract product;
5. Manufacture product for clinical trial of contract product;
6. Clinical trial of the contract product;
7. Establishment of manufacturing technology and SOP of contract product;
8. Establishment of quality control test method and SOP of contract product;
9. Preparation of safety/efficacy data of contract product;
10. Establishment and operation of GMP (good manufacturing practice) facility of contract product;
11. Biologics licence application (BLA) of contract product;
12. Obtaining the product registration and (conditional) sales permit for contract product.

Pharos and BPK have agreed on the exclusive manufacturing and marketing rights of anti-CD19 CAR-T-cell products for 15 years from the starting date of sales in the markets. The territories BPK shall have exclusive rights under this agreement are all the countries, except China.

2. Provide a general overview and discussion of the activities of management

Biocure Technology Inc.'s Biocure Pharm Corp. (BPK) has entered into an agreement with Pharos Vaccine Inc. for the development of overseas market of CAR-T-cell products on an exclusive basis. The two companies will work together in developing anti-CD19 CAR-T-cell therapy products, conducting preclinical and clinical trials, and commercializing anti-CD19 CAR-T-cell therapy products overseas to treat leukemia and lymphoma patients. Some of the highlights of collaborative research and development work scopes in the agreement include:

1. **Manufacture products for preclinical trial of contract product;**
2. **Preclinical trial of contract product;**
3. **Manufacture three batches of test product for clinical trial application of contract product;**
4. **Application for clinical trial of contract product;**
5. **Manufacture product for clinical trial of contract product;**
6. **Clinical trial of the contract product;**
7. **Establishment of manufacturing technology and SOP of contract product;**
8. **Establishment of quality control test method and SOP of contract product;**
9. **Preparation of safety/efficacy data of contract product;**
10. **Establishment and operation of GMP (good manufacturing practice) facility of contract product;**
11. **Biologics licence application (BLA) of contract product;**
12. **Obtaining the product registration and (conditional) sales permit for contract product.**

Pharos and BPK have agreed on the exclusive manufacturing and marketing rights of anti-CD19 CAR-T-cell products for 15 years from the starting date of sales in the markets. The territories BPK shall have exclusive rights under this agreement are all the countries, except China.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Not applicable to the issuer during the month of May 2019

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not applicable to the issuer during the month of May 2019

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable to the issuer during the month of May 2019

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship..

Not applicable to the issuer during the month of May 2019

8. Describe the acquisition of new customers or loss of customers.

Not applicable to the issuer during the month of May 2019

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Not applicable to the issuer during the month of May 2019

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.
Not applicable to the issuer during the month of May 2019
11. Report on any labour disputes and resolutions of those disputes if applicable.
Not applicable to the issuer during the month of May 2019
12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
Not applicable to the issuer during the month of May 2019
13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
Other than in relation to accounts payable incurred by the Issuer in the ordinary course of business with its service providers, not applicable to the issuer during the month of May 2019.
14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
NA	NA	NA	NA

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.
Not applicable to the issuer during the month of May 2019
16. Provide details of any changes in directors, officers or committee members.
Not applicable to the issuer during the month of May 2019
17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.
Not applicable to the issuer during the month of May 2019

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated June 3rd, 2019.

Konstantin Lichtenwald
Name of Director or Senior Officer

"Konstantin Lichtenwald"
Signature
CFO and Director
Official Capacity

Issuer Details Name of Issuer	For Month End	Date of Report YY/MM/D
BIOCURE TECHNOLOGY INC	May 2019	19/06/03
Issuer Address		
300-1055 West Hastings Street		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Vancouver BC, V6E 2E9	(604) 685 5120	(604) 609 7146
Contact Name	Contact Position	Contact Telephone No.
Konstantin Lichtenwald	Director	(604) 609 7146
Contact Email Address	Web Site Address	
klichtenwald@bicuretech.com	www.biocuretech.com	